Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma

Keiichi Ito, Ayako Masunaga, Nobuyuki Tanaka, Ryuichi Mizuno, Suguru Shirotake, Yota Yasumizu, Yujiro Ito, Yasumasa Miyazaki, Masayuki Hagiwara, Kent Kanao, Shuji Mikami, Tetsuo Momma, Takeshi Masuda, Ken Nakagawa, Masafumi Oyama, Tomohiko Asano, Mototsugu Oya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: Progression-free survival of first-line targeted therapy greatly influences the survival of patients with metastatic renal cell carcinoma. We evaluated whether post-treatment inflammatory markers and lactate dehydrogenase levels had impacts on progression-free survival prediction in addition to those of conventional predictors. Methods: Two hundred and fifteen patients whose tumors were clear cell type and in whom first-line targeted therapies could be continued for >1 month were evaluated. Pretreatment clinical factors, pathological factors and laboratory data 1 month after targeted therapy initiation-including inflammatory markers (neutrophil count, neutrophil-to-lymphocyte ratio and C-reactive protein) and lactate dehydrogenase-were reviewed. To identify progression-free survival predictors, multivariate analyses were done. Results: The 1-year progression-free survival rate was 47%. Female gender, Karnofsky performance status <80%, time from diagnosis to systemic treatment <12 months, pretreatment C-reactive protein >3.0 mg/dl and post-treatment neutrophil-to-lymphocyte ratio >3.0 were independent predictors for progression-free survival. In contrast, neither C-reactive protein increase nor neutrophil-to-lymphocyte ratio increase after targeted therapy initiation were independent predictors. Pretreatment lactate dehydrogenase, post-treatment lactate dehydrogenase and lactate dehydrogenase decline were not independent predictors. When all patients were stratified by these independent factors into three groups (0 risk vs. 1 or 2 risks vs. 3 or more risks), there were significant differences in progression-free survival rates between the groups (P < 0.0001). Furthermore, there were also significant differences in overall survival rates between the groups (P < 0.0001). Conclusions: Integration of post-treatment neutrophil-to-lymphocyte ratio value with pretreatment factors may lead to the establishment of effective predictive model for disease progression in patients with metastatic clear cell renal cell carcinoma who received first-line targeted therapies.

Original languageEnglish
Pages (from-to)69-76
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume49
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Disease-Free Survival
L-Lactate Dehydrogenase
Neutrophils
Lymphocytes
Therapeutics
Survival Rate
C-Reactive Protein
Karnofsky Performance Status
Clear-cell metastatic renal cell carcinoma
Renal Cell Carcinoma
Disease Progression
Multivariate Analysis
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. / Ito, Keiichi; Masunaga, Ayako; Tanaka, Nobuyuki; Mizuno, Ryuichi; Shirotake, Suguru; Yasumizu, Yota; Ito, Yujiro; Miyazaki, Yasumasa; Hagiwara, Masayuki; Kanao, Kent; Mikami, Shuji; Momma, Tetsuo; Masuda, Takeshi; Nakagawa, Ken; Oyama, Masafumi; Asano, Tomohiko; Oya, Mototsugu.

In: Japanese Journal of Clinical Oncology, Vol. 49, No. 1, 01.01.2019, p. 69-76.

Research output: Contribution to journalArticle

Ito, Keiichi ; Masunaga, Ayako ; Tanaka, Nobuyuki ; Mizuno, Ryuichi ; Shirotake, Suguru ; Yasumizu, Yota ; Ito, Yujiro ; Miyazaki, Yasumasa ; Hagiwara, Masayuki ; Kanao, Kent ; Mikami, Shuji ; Momma, Tetsuo ; Masuda, Takeshi ; Nakagawa, Ken ; Oyama, Masafumi ; Asano, Tomohiko ; Oya, Mototsugu. / Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma. In: Japanese Journal of Clinical Oncology. 2019 ; Vol. 49, No. 1. pp. 69-76.
@article{5dc094f006984a749bfe5c6dbdc69e25,
title = "Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma",
abstract = "Objectives: Progression-free survival of first-line targeted therapy greatly influences the survival of patients with metastatic renal cell carcinoma. We evaluated whether post-treatment inflammatory markers and lactate dehydrogenase levels had impacts on progression-free survival prediction in addition to those of conventional predictors. Methods: Two hundred and fifteen patients whose tumors were clear cell type and in whom first-line targeted therapies could be continued for >1 month were evaluated. Pretreatment clinical factors, pathological factors and laboratory data 1 month after targeted therapy initiation-including inflammatory markers (neutrophil count, neutrophil-to-lymphocyte ratio and C-reactive protein) and lactate dehydrogenase-were reviewed. To identify progression-free survival predictors, multivariate analyses were done. Results: The 1-year progression-free survival rate was 47{\%}. Female gender, Karnofsky performance status <80{\%}, time from diagnosis to systemic treatment <12 months, pretreatment C-reactive protein >3.0 mg/dl and post-treatment neutrophil-to-lymphocyte ratio >3.0 were independent predictors for progression-free survival. In contrast, neither C-reactive protein increase nor neutrophil-to-lymphocyte ratio increase after targeted therapy initiation were independent predictors. Pretreatment lactate dehydrogenase, post-treatment lactate dehydrogenase and lactate dehydrogenase decline were not independent predictors. When all patients were stratified by these independent factors into three groups (0 risk vs. 1 or 2 risks vs. 3 or more risks), there were significant differences in progression-free survival rates between the groups (P < 0.0001). Furthermore, there were also significant differences in overall survival rates between the groups (P < 0.0001). Conclusions: Integration of post-treatment neutrophil-to-lymphocyte ratio value with pretreatment factors may lead to the establishment of effective predictive model for disease progression in patients with metastatic clear cell renal cell carcinoma who received first-line targeted therapies.",
author = "Keiichi Ito and Ayako Masunaga and Nobuyuki Tanaka and Ryuichi Mizuno and Suguru Shirotake and Yota Yasumizu and Yujiro Ito and Yasumasa Miyazaki and Masayuki Hagiwara and Kent Kanao and Shuji Mikami and Tetsuo Momma and Takeshi Masuda and Ken Nakagawa and Masafumi Oyama and Tomohiko Asano and Mototsugu Oya",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/jjco/hyy154",
language = "English",
volume = "49",
pages = "69--76",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma

AU - Ito, Keiichi

AU - Masunaga, Ayako

AU - Tanaka, Nobuyuki

AU - Mizuno, Ryuichi

AU - Shirotake, Suguru

AU - Yasumizu, Yota

AU - Ito, Yujiro

AU - Miyazaki, Yasumasa

AU - Hagiwara, Masayuki

AU - Kanao, Kent

AU - Mikami, Shuji

AU - Momma, Tetsuo

AU - Masuda, Takeshi

AU - Nakagawa, Ken

AU - Oyama, Masafumi

AU - Asano, Tomohiko

AU - Oya, Mototsugu

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: Progression-free survival of first-line targeted therapy greatly influences the survival of patients with metastatic renal cell carcinoma. We evaluated whether post-treatment inflammatory markers and lactate dehydrogenase levels had impacts on progression-free survival prediction in addition to those of conventional predictors. Methods: Two hundred and fifteen patients whose tumors were clear cell type and in whom first-line targeted therapies could be continued for >1 month were evaluated. Pretreatment clinical factors, pathological factors and laboratory data 1 month after targeted therapy initiation-including inflammatory markers (neutrophil count, neutrophil-to-lymphocyte ratio and C-reactive protein) and lactate dehydrogenase-were reviewed. To identify progression-free survival predictors, multivariate analyses were done. Results: The 1-year progression-free survival rate was 47%. Female gender, Karnofsky performance status <80%, time from diagnosis to systemic treatment <12 months, pretreatment C-reactive protein >3.0 mg/dl and post-treatment neutrophil-to-lymphocyte ratio >3.0 were independent predictors for progression-free survival. In contrast, neither C-reactive protein increase nor neutrophil-to-lymphocyte ratio increase after targeted therapy initiation were independent predictors. Pretreatment lactate dehydrogenase, post-treatment lactate dehydrogenase and lactate dehydrogenase decline were not independent predictors. When all patients were stratified by these independent factors into three groups (0 risk vs. 1 or 2 risks vs. 3 or more risks), there were significant differences in progression-free survival rates between the groups (P < 0.0001). Furthermore, there were also significant differences in overall survival rates between the groups (P < 0.0001). Conclusions: Integration of post-treatment neutrophil-to-lymphocyte ratio value with pretreatment factors may lead to the establishment of effective predictive model for disease progression in patients with metastatic clear cell renal cell carcinoma who received first-line targeted therapies.

AB - Objectives: Progression-free survival of first-line targeted therapy greatly influences the survival of patients with metastatic renal cell carcinoma. We evaluated whether post-treatment inflammatory markers and lactate dehydrogenase levels had impacts on progression-free survival prediction in addition to those of conventional predictors. Methods: Two hundred and fifteen patients whose tumors were clear cell type and in whom first-line targeted therapies could be continued for >1 month were evaluated. Pretreatment clinical factors, pathological factors and laboratory data 1 month after targeted therapy initiation-including inflammatory markers (neutrophil count, neutrophil-to-lymphocyte ratio and C-reactive protein) and lactate dehydrogenase-were reviewed. To identify progression-free survival predictors, multivariate analyses were done. Results: The 1-year progression-free survival rate was 47%. Female gender, Karnofsky performance status <80%, time from diagnosis to systemic treatment <12 months, pretreatment C-reactive protein >3.0 mg/dl and post-treatment neutrophil-to-lymphocyte ratio >3.0 were independent predictors for progression-free survival. In contrast, neither C-reactive protein increase nor neutrophil-to-lymphocyte ratio increase after targeted therapy initiation were independent predictors. Pretreatment lactate dehydrogenase, post-treatment lactate dehydrogenase and lactate dehydrogenase decline were not independent predictors. When all patients were stratified by these independent factors into three groups (0 risk vs. 1 or 2 risks vs. 3 or more risks), there were significant differences in progression-free survival rates between the groups (P < 0.0001). Furthermore, there were also significant differences in overall survival rates between the groups (P < 0.0001). Conclusions: Integration of post-treatment neutrophil-to-lymphocyte ratio value with pretreatment factors may lead to the establishment of effective predictive model for disease progression in patients with metastatic clear cell renal cell carcinoma who received first-line targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=85059494847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059494847&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyy154

DO - 10.1093/jjco/hyy154

M3 - Article

C2 - 30407543

AN - SCOPUS:85059494847

VL - 49

SP - 69

EP - 76

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

ER -